Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIRO5 trial in initially unresectable liver-only metastatic colorectal cancer
2013-005435-24Phase 3Active
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Feb 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, folinic acid, panitumumab, bevacizumab, oxaliplatin and 1 more in colorectal cancer (CRC) (3 arms), sponsored by Dutch Colorectal Cancer Group. Primary endpoints: Progression-free survival and R0/1 resection rate. Started Feb 2014; status: active.
02
Drugs
irinotecanfolinic acidpanitumumabbevacizumaboxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2013-005435-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005435-24.